SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-----------------------
Date of Report (Date of earliest event reported):
September 29, 2004
Alpharma Inc.
-------------
(Exact name of registrant as specified in its charter)
Delaware 1-8593 22-2095212
-------- ------ ----------
(State or other jurisdiction (Commission File (IRS Employer Identification)
of incorporation) Number)
One Executive Drive, Fort Lee, New Jersey 07024
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(201) 947-7774
--------------
Not Applicable
------------------------------------------------
(Former name or former address, if changed since
last report)
Item 1.01 ENTRY INTO A DEFINITIVE MATERIAL AGREEMENT
On September 24, 2004 Alpharma Inc. (the "Company") and Purepac
Pharmaceutical Co. (a subsidiary of Alpharma Inc), on the one hand and Teva
Pharmaceutical Industries Ltd. ("Teva") and Plantex USA, Inc., a subsidiary of
Teva, on the other hand, entered in Amendment Number One (the "Amendment") to
an Agreement between the parties, dated April 26, 2004 (the "Waiver Agreement")
and an Amended and Restated Supply Agreement between the parties, dated April
26, 2004 (the "Supply Agreement" and together with the Waiver Agreement, the
"Original Agreements").
The Amendment provides that the indemnification provision set forth
in the Original Agreements applies to an Alpharma commercial launch that occurs
at an earlier point in time than provided in the Original Agreements. In
certain circumstances, Alpharma shall pay Teva more consideration than set
forth in the Original Agreements. The Company has also agreed to certain
notification requirements regarding its pending gabapentin tablet product.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALPHARMA INC.
By: /s/ Robert F. Wrobel
--------------------
Name: Robert F. Wrobel
Title: Executive Vice President
Date: September 29, 2004